According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
Other research analysts have also issued reports about the company. Roth Capital reaffirmed a buy rating and set a $5.00 target price on shares of Actinium Pharmaceuticals in a report on Wednesday, September 28th. FBR & Co set a $9.00 price target on Actinium Pharmaceuticals and gave the company a buy rating in a research report on Thursday, July 21st.
Actinium Pharmaceuticals (NYSEMKT:ATNM) opened at 1.14 on Tuesday. The stock’s market capitalization is $54.40 million. Actinium Pharmaceuticals has a 12-month low of $1.08 and a 12-month high of $3.50. The firm has a 50-day moving average of $1.59 and a 200-day moving average of $1.76.
In other Actinium Pharmaceuticals news, major shareholder Sloan-Kettering Cance Memorial sold 192,927 shares of Actinium Pharmaceuticals stock in a transaction that occurred on Wednesday, August 31st. The stock was sold at an average price of $1.83, for a total value of $353,056.41. Following the transaction, the insider now directly owns 4,878,988 shares of the company’s stock, valued at approximately $8,928,548.04. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Several hedge funds have recently made changes to their positions in ATNM. GSA Capital Partners LLP purchased a new stake in shares of Actinium Pharmaceuticals during the second quarter valued at $247,000. BlackRock Institutional Trust Company N.A. raised its stake in shares of Actinium Pharmaceuticals by 11.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 462,683 shares of the company’s stock valued at $819,000 after buying an additional 47,131 shares during the last quarter. BlackRock Fund Advisors raised its stake in shares of Actinium Pharmaceuticals by 31.5% in the second quarter. BlackRock Fund Advisors now owns 102,003 shares of the company’s stock valued at $181,000 after buying an additional 24,453 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Actinium Pharmaceuticals by 19.2% in the second quarter. Vanguard Group Inc. now owns 1,581,228 shares of the company’s stock valued at $2,798,000 after buying an additional 254,318 shares during the last quarter.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.